UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 20, 2012
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware |
|
001-34637 |
|
20-1852016 |
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
25801 Industrial Boulevard, Suite B, Hayward, |
|
94545 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 20, 2012, Anthera Pharmaceuticals, Inc. (Anthera) received a letter from The Nasdaq Stock Market informing Anthera that for the last 30 consecutive business days the bid price of Antheras common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Listing Rule 5450(a)(1). The letter stated that Nasdaq will provide Anthera a grace period of 180 calendar days, or until June 18, 2013, to regain compliance. To regain compliance, any time before June 18, 2013, the bid price of Antheras common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Anthera Pharmaceuticals, Inc. | |
|
| |
|
| |
Date: December 21, 2012 |
By: |
/s/ Christopher P. Lowe |
|
|
Christopher P. Lowe |
|
|
Chief Financial Officer |